6:11 PM
 | 
Sep 25, 2013
 |  BC Extra  |  Clinical News

Infinity drops Hsp90 inhibitor retaspimycin

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) said it will discontinue development of retaspimycin ( IPI-504) after the compound missed the co-primary endpoints in a Phase II trial to treat non-small cell lung cancer (NSCLC). Retaspimycin plus docetaxel did not significantly improve...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >